Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2026-02-26 @ 2:15 AM
Study NCT ID:
NCT06137794
Status:
UNKNOWN
Last Update Posted:
2023-11-18
First Post:
2023-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Application of "I-Anticoagulation"in Patients With Atrial Fibrillation
Sponsor:
RenJi Hospital
Organization:
Study Overview
Official Title:
Application of the Anticoagulation Decision-making and Management Model Based on the "I-Anticoagulation" Tool in Patients With Atrial Fibrillation: A Prospective, Multicenter, Cluster Randomized Controlled Study
Status:
UNKNOWN
Status Verified Date:
2023-11
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this prospective, multicenter, cluster randomized controlled trial is to assess the effectiveness of a shared decision-making tool, "I-Anticoagulation", for anticoagulation management in AF patients. The main questions it aims to answer are:
* whether "I-Anticoagulation" could help improve the rational use of anticoagulants in AF patients;
* whether "I-Anticoagulation" could help increase the adherence and satisfaction of AF patients receiving anticoagulants.
The anticoagulation therapy of AF patients will be determined by clinicians with the use of "I-Anticoagulation", and AF patients will be managed using "I-Anticoagulation" during their anticoagulation therapy.
Researchers will compare the outcomes with the control group, in which patients with AF will receive standard care.
* whether "I-Anticoagulation" could help improve the rational use of anticoagulants in AF patients;
* whether "I-Anticoagulation" could help increase the adherence and satisfaction of AF patients receiving anticoagulants.
The anticoagulation therapy of AF patients will be determined by clinicians with the use of "I-Anticoagulation", and AF patients will be managed using "I-Anticoagulation" during their anticoagulation therapy.
Researchers will compare the outcomes with the control group, in which patients with AF will receive standard care.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: